the optimum duration of bisphosphonate therapy in management of osteoporosis has not been established
there is trial evidence relating to comparing the effects of discontinuing alendronate treatment after 5 years vs continuing for 10 years
this study revealed that women who discontinued alendronate after 5 years showed a moderate decline in BMD and a gradual rise in biochemical markers but no higher fracture risk other than for clinical vertebral fractures compared with those who continued alendronate
the authors concluded that the study results suggest that for many women, discontinuation of alendronate for up to 5 years does not appear to significantly increase fracture risk. However, women at very high risk of clinical vertebral fractures may benefit by continuing beyond 5 years
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.